SGRY · XBRL financial data
Surgery Partners financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (SGRY's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative | 37 | 21* | 33 | 40 | 29 | 36* | 36 | 36 | 22 | 24* | 39 | 36 |
| Total operating expenses | 592 | 634* | 641 | 677 | 710 | 737* | 714 | 715 | 716 | 775* | 745 | 747 |
| Operating income (loss) | 83 | 101* | 76 | 85 | 61 | 127* | 62 | 112 | 106 | 110* | 66 | 102 |
| Other income (expense) | 1 | 1* | 0 | (5) | 1 | — | — | — | — | — | — | — |
| Income tax expense (benefit) | 3 | 6* | 4 | 5 | 5 | 121* | 0 | (1) | 6 | 14* | (1) | 3 |
| Net income (loss) | (5) | (1)* | (12) | (16) | (32) | (109)* | (38) | (3) | (23) | (15)* | (36) | (15) |
| Earnings per share, basic USD per share | (0.04) | (0.01)* | (0.10) | (0.12) | (0.25) | (0.86)* | (0.30) | (0.02) | (0.18) | (0.12)* | (0.28) | (0.12) |
| Earnings per share, diluted USD per share | (0.04) | (0.01)* | (0.10) | (0.12) | (0.25) | (0.86)* | (0.30) | (0.02) | (0.18) | (0.12)* | (0.28) | (0.12) |
| Weighted average shares, basic millions of shares | 126 | 126* | 126 | 126 | 126 | 126* | 127 | 127 | 127 | 128* | 128 | 129 |
| Weighted average shares, diluted millions of shares | 126 | 124* | 126 | 126 | 126 | 126* | 127 | 127 | 127 | 128* | 128 | 129 |
Balance sheet
CSVFiscal quarters (SGRY's year ends in late December)
Cash flows
CSVFiscal quarters (SGRY's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (5) | (1)* | (12) | (16) | (32) | (109)* | (38) | (3) | (23) | (15)* | (36) | (15) |
| Stock-based compensation | 4 | 5* | 5 | 15 | 7 | 6* | 8 | 7* | 3* | (2)* | 6 | 4* |
| Depreciation and amortization | 29 | 31* | 34 | 35 | 50 | 34* | 36 | 40 | 40 | 60* | 39 | 39 |
| Net cash from operating activities | 105* | 63* | 41 | 83* | 65* | 111* | 6 | 81* | 84* | 103* | 12 | 59* |
| Purchases of property and equipment | 19* | 20* | 21 | 27* | 20* | 22* | 23 | 23* | 20* | 13* | 16 | 22* |
| Net cash from investing activities | (26)* | (58)* | (83) | (244)* | (50)* | (112)* | (76) | 2* | (46)* | (126)* | (13) | (20)* |
| Proceeds from issuing common stock | — | year only | — | — | — | year only | — | — | — | — | — | — |
| Proceeds from long-term debt | 93* | 707* | 193 | 1,103* | 168* | 266* | 214 | 169* | 128* | 693* | 195 | 155* |
| Repayments of long-term debt | 76* | 700* | 120 | 854* | 135* | 171* | 119 | 180* | 161* | 579* | 194 | 116* |
| Net cash from financing activities | (20)* | (45)* | 32 | 190* | (7)* | 48* | 30 | (63)* | (84)* | 59* | (56) | (5)* |
| Net change in cash | 59* | (40)* | (11) | 28* | 8* | 48* | (40) | 21* | (47)* | 37* | (58) | 34* |
Compare with peers
SIC 8062 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8062 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Surgery Partners | 217 | not reported | 59* | 130.9M | 10-QJun 30, 2026 |
| Select Medical Holdings | 26 | 1,421 | 38 | 124.0M | 10-QMar 31, 2026 |
| Pediatrix Medical Group | 312 | 501 | 117* | 78.1M | 10-QSep 30, 2026 |
| Universal Health Services | 139 | 4,638 | 443* | not reported | 10-QJun 30, 2026 |
| Tenet Healthcare | 2,674 | 5,631 | 1,281* | 79.6M | 10-QSep 30, 2026 |
| Encompass Health | 76 | 1,610 | 362* | 98.1M | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.